Windtree Therapeutics Files 8-K
Ticker: WINTW · Form: 8-K · Filed: Sep 30, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-reporting
TL;DR
Windtree Therapeutics filed an 8-K on 9/30/24. Check it for updates.
AI Summary
Windtree Therapeutics, Inc. filed an 8-K on September 30, 2024, reporting on other events and financial statements. The company, formerly known as Discovery Laboratories Inc. and Ansan Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Warrington, Pennsylvania.
Why It Matters
This filing provides an update on Windtree Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Numbers
- 001-39290 — SEC File Number (Identifies the company's filing history with the SEC.)
- 94-3171943 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Discovery Laboratories Inc. /DE/ (company) — Former Company Name
- Ansan Pharmaceuticals Inc (company) — Former Company Name
- September 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Warrington, Pennsylvania (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported, only that this item is included in the filing.
What is the primary business of Windtree Therapeutics, Inc.?
Windtree Therapeutics, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
When did Windtree Therapeutics, Inc. change its name from Discovery Laboratories Inc.?
The date of name change from Discovery Laboratories Inc. /DE/ was December 1, 1997.
What is the address of Windtree Therapeutics' principal executive offices?
The principal executive offices are located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
What is the fiscal year end for Windtree Therapeutics, Inc.?
The fiscal year end for Windtree Therapeutics, Inc. is December 31.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-30 08:22:10
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240929_8k.htm (8-K) — 24KB
- ex_728287.htm (EX-99.1) — 26KB
- pic1.jpg (GRAPHIC) — 4KB
- 0001437749-24-030219.txt ( ) — 194KB
- wint-20240930.xsd (EX-101.SCH) — 3KB
- wint-20240930_def.xml (EX-101.DEF) — 11KB
- wint-20240930_lab.xml (EX-101.LAB) — 15KB
- wint-20240930_pre.xml (EX-101.PRE) — 11KB
- wint20240929_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On September 30, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing positive topline clinical results for the Company's Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients in early cardiogenic shock. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 30, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer